Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
Mei-Ping Chen, Di-Xuan Jiang, Jia-Xi Rang, Hai-Bo Zhuo, Zhi-Guo Zhou
Scientific Reports, doi:10.1038/s41598-024-53862-y
This study aimed to explore the effectiveness and safety of azvudine, nirmatrelvir/ritonavir, and molnupiravir in adult patients with mild-to-moderate COVID-19. This retrospective cohort study included patients with mild-to-moderate COVID-19 (asymptomatic, mild, and common types) at the First Hospital of Changsha (Hunan Province, China) between March and November 2022. Eligible patients were classified into the azvudine, nirmatrelvir/ritonavir, or molnupiravir groups according to the antiviral agents they received. The outcomes were the times to nucleic acid negative conversion (NANC). This study included 157 patients treated with azvudine (n = 66), molnupiravir (n = 66), or nirmatrelvir/ritonavir (n = 25). There were no statistically significant differences in the time from diagnosis to NANC among the azvudine, molnupiravir, and nirmatrelvir/ritonavir groups [median, 9 (95% CI 9-11) vs. 11 (95% CI 10-12) vs. 9 (95% CI 8-12) days, P = 0.15], time from administration to NANC [median, 9 (95% CI 8-10) vs. 10 (95% CI 9.48-11) vs. 8.708 (95% CI 7.51-11) days, P = 0.50], or hospital stay [median, 11 (95% CI 11-13) vs. 13 (95% CI 12-14) vs. 12 (95% CI 10-14) days, P = 0.14], even after adjustment for sex, age, COVID-19 type, comorbidities, Ct level, time from diagnosis to antiviral treatment, and number of symptoms. The cumulative NANC rates in the azvudine, molnupiravir, and nirmatrelvir/ritonavir groups were 15.2%/12.3%/16.0% at day 5 (P = 0.858), 34.8%/21.5%/32.0% at day 7 (P = 0.226), 66.7%/52.3%/60.0% at 10 days (P = 0.246), and 86.4%/86.2%/80.0% at day 14 (P = 0.721). No serious adverse events were reported. Azvudine may be comparable to nirmatrelvir/ritonavir and molnupiravir in adult patients with mild-to-moderate COVID-19 regarding time to NANC, hospital stay, and AEs.
Author contributions Z.G.Z. and M.P.C. conceived and coordinated the study, designed, performed and analyzed the experiments, wrote the paper. D.X.J., J.X.R. and H.B.Z. carried out the data collection, data analysis, and revised the paper. All authors reviewed the results and approved the final version of the manuscript.
Competing interests The authors declare no competing interests.
References
Anderson, Caubel, Rusnak, Investigators, Nirmatrelvir-ritonavir and viral load rebound in Covid-19, N. Engl. J. Med
Bernal, Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients, N. Engl. J. Med
Butler, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): An open-label, platform-adaptive randomised controlled trial, Lancet
Casalini, Giacomelli, Antinori, Liver tests abnormalities with licensed antiviral drugs for COVID-19: A narrative review, Expert Opin. Drug Saf
Charness, Rebound of SARS-CoV-2 infection after nirmatrelvir-ritonavir treatment, N. Engl. J. Med
Consortium, Repurposed antiviral drugs for Covid-19-Interim WHO solidarity trial results, N. Engl. J. Med
Da Silva, Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19, Front. Med
Dryden-Peterson, Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. Health system: A population-based cohort study, Ann. Intern. Med
Gao, Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19, J. Infect
Gao, Liu, Li, Xu, Zhang et al., Molnupiravir for treatment of adults with mild or moderate COVID-19: A systematic review and meta-analysis of randomized controlled trials, Clin. Microbiol. Infect
Grandvuillemin, Rocher, Valnet-Rabier, Drici, Dautriche et al., Pharmacovigilance follow-up of patients in the context of the COVID-19 pandemic, Therapie
Hammond, Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19, N. Engl. J. Med
Izzedine, Jhaveri, Perazella, COVID-19 therapeutic options for patients with kidney disease, Kidney Int
Kale, Shelke, Dagar, Anders, Gaikwad, How to use COVID-19 antiviral drugs in patients with chronic kidney disease, Front. Pharmacol
Khoo, Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): A randomised, placebo-controlled, double-blind, phase 2 trial, Lancet Infect. Dis
Koelle, Martin, Antia, Lopman, Dean, The changing epidemiology of SARS-CoV-2, Science
Lory, Safety profile of the lopinavir/ritonavir combination before and during the SARS-CoV-2 pandemic, Therapie
Niu, Ji, Zhao, Lei, Timing and magnitude of the second wave of the COVID-19 Omicron variant-189 Countries and Territories, November 2021 to, China CDC Wkly
Painter, Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2, Antimicrob. Agents Chemother
Parums, Editorial: Rebound COVID-19 and cessation of antiviral treatment for SARS-CoV-2 with paxlovid and molnupiravir, Med. Sci. Monit
Petrakis, Rafailidis, Trypsianis, Papazoglou, Panagopoulos, The antiviral effect of nirmatrelvir/ritonavir during COVID-19 pandemic real-world data, Viruses
Przekop, Gruszewska, Chrostek, Liver function in COVID-19 infection, World J. Hepatol
Qu, Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA, Cell Host Microbe
Ren, A randomized, open-label, controlled clinical trial of azvudine tablets in the treatment of mild and common COVID-19, a pilot study, Adv. Sci
Ren, Wang, Gao, Zhou, Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance, World J. Clin. Cases
Rothan, Byrareddy, The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak, J. Autoimmun
Rubin, From positive to negative to positive again-the mystery of why COVID-19 rebounds in some patients who take paxlovid, JAMA
Sun, Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: A retrospective cohort study, ClinicalMedicine
Vassilopoulos, Mylonakis, In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death, Ann. Intern. Med
Vujcic, Outcomes of COVID-19 among patients with liver disease, World J. Gastroenterol
Wang, Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants, Cell
Wiersinga, Rhodes, Cheng, Peacock, Prescott, Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): A review, JAMA
Yu, Liver injury in COVID-19: Clinical features and treatment management, Virol. J
Zhang, Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients, Signal Transduct. Target. Ther
Zhou, Clinical characteristics of older and younger patients infected with SARS-CoV-2, Aging
Zhou, Low-dose corticosteroid combined with immunoglobulin reverses deterioration in severe cases with COVID-19, Signal Transduct. Target. Ther
